STAT+: Natural killer cells, primed with an antibody, induce remissions in patients with advanced lymphoma

Affimed’s AFM13 engager is a "matchmaker." When it is coupled with NK cells, it connects them to tumor cells. When that happens, cancer cells die.

An experimental immunotherapy involving so-called natural killer cells elicited complete remissions in a majority of patients with advanced Hodgkin lymphoma, researchers reported Sunday.

In the study, eight of the 13 patients given an optimized dose and schedule of the therapy saw their tumor cells completely disappear with minimal side effects. The new data improve upon initial results presented last year, although it remains unclear how long the responses will last.

Continue to STAT+ to read the full story…